The G-protein coupled estrogen receptor (GPER/GPR30) is a gonadotropin receptor dependent positive prognosticator in ovarian carcinoma patients.
The G-protein coupled estrogen receptor (GPER/GPR30) is a gonadotropin receptor dependent positive prognosticator in ovarian carcinoma patients.
复制标题
DOI：
10.1371/journal.pone.0071791
复制
发表时间：
2013
期刊：
影响因子：
3.7
通讯作者：
Lenhard M
中科院分区：
文献类型：
--
作者：
Heublein S;Mayr D;Vrekoussis T;Friese K;Hofmann SS;Jeschke U;Lenhard M
刺激雌激素受体（FSHR）和黄体生成赛（LHCGR）的卵泡被证明会影响患有上皮卵巢癌患者的存活率（EOC）。 /lhcgr，其对EOC的预后影响仍然有争议。因此，在治疗反应和提示方面的行为可能有所不同。在FSHR/LHCGR上的肿瘤免疫表型。在EOC组织中活化的FSHR/LHCGR的情况下，GPER与FSHR/LHCGR相关，并且仅在FSHR/LHCGR阴性患者中延长了总体存活率。 GPER激动剂（4-羟基tamoxifen，G1）仅在LH/FSH未刺激的情况下降低了EOC细胞的增殖方向，只有LHCGR/FSHR阴性的患者在我们的生存方面似乎会从GPER中获得，并且体外结果支持GPER激活在LHCGR/FSHR阴性EOC患者中可能具有治疗益处。评估GPER激活对临床方案的影响。
Follicle stimulating hormone receptor (FSHR) and luteinizing hormone receptor (LHCGR) were demonstrated to impact upon survival of patients suffering from epithelial ovarian cancer (EOC). Though structure wise the G-protein coupled estrogen receptor (GPER/GPR30) is related to FSHR/LHCGR, its prognostic impact in EOC remains controversial. We recently found that FSHR negative patients represent a specific EOC subgroup that may behave differently in respect to both treatment response and prognosis. Hence, the current study aimed to analyze how GPER may interact with the FSHR/LHCGR system in EOC and whether the prognostic significance of GPER in EOC cases (n = 151) may be dependent on the FSHR/LHCGR immunophenotype of the tumor. Ovarian cancer cell lines were used to study how FSH and LH regulate GPER and whether GPER activation differentially affects in vitro cell proliferation in presence/absence of activated FSHR/LHCGR. In EOC tissue, GPER correlated with FSHR/LHCGR and was related to prolonged overall survival only in FSHR/LHCGR negative patients. Although GPER was found to be specifically induced by LH/FSH, GPER agonists (4-Hydroxy-Tamoxifen, G1) reduced EOC cell proliferation only in case of LH/FSH unstimulated pathways. To the same direction, only patients characterized as LHCGR/FSHR negative seem to gain from GPER in terms of survival. Our combined tissue and in vitro results support thus the hypothesis that GPER activation could be of therapeutic benefit in LHCGR/FSHR negative EOC patients. Further studies are needed to evaluate the impact of GPER activation on a clinical scheme.
登录
查看更多内容
影响因子：
11.2
作者：
Ariazi EA;Brailoiu E;Yerrum S;Shupp HA;Slifker MJ;Cunliffe HE;Black MA;Donato AL;Arterburn JB;Oprea TI;Prossnitz ER;Dun NJ;Jordan VC
通讯作者：
Jordan VC
在卵巢癌病例中，HER-2/NEU表达是不表达卵泡刺激激素受体（FSHR）的阴性预后剂。
影响因子：
4
作者：
Heublein S;Vrekoussis T;Mayr D;Friese K;Lenhard M;Jeschke U;Dian D
通讯作者：
Dian D
影响因子：
3.8
作者：
Jala VR;Radde BN;Haribabu B;Klinge CM
通讯作者：
Klinge CM
影响因子：
4
作者：
Kolkova Z;Casslén V;Henic E;Ahmadi S;Ehinger A;Jirström K;Casslén B
通讯作者：
Casslén B
影响因子：
3.7
作者：
Cheng W;Chen L;Yang S;Han J;Zhai D;Ni J;Yu C;Cai Z
通讯作者：
Cai Z